Filing Flows › Prelude Therapeutics (PRLD) › Q3 2025
Prelude Therapeutics (PRLD) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Prelude Therapeutics (PRLD) reported revenue of $6.5M for the third quarter 2025 (Q3 2025), +117% from a year earlier. Operating margin was -314.1%, net loss $19.7M (303.5% of revenue).
Prelude Therapeutics, Q3 2025: revenue $6.5M (+117% year over year), operating margin -314.1%, net loss $19.7M, operating cash flow −$19.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.5M | — | +117% |
| Operating profit | −$20.4M | — | — |
| Net earnings | −$19.7M | — | — |
| Operating cash flow | −$19.1M | — | — |
What changed
Revenue was $6.5M in Q3 2025, up 117% year over year.
Operating costs exceeded revenue by $20.4M, an operating margin of -314.1%. Total costs fell 28% while revenue rose 117%. The quarter ended with a net loss of $19.7M.
Operating cash flow was −$19.1M. Non-cash charges added back $425K of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $2.2M.
Questions
What was Prelude Therapeutics' revenue in the third quarter 2025?
Prelude Therapeutics (PRLD) reported revenue of $6.5M for the third quarter 2025 (Q3 2025), +117% from a year earlier.
Was Prelude Therapeutics profitable in the third quarter 2025?
Operating loss was $20.4M (-314.1% of revenue) and net loss $19.7M.